Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin 10 mg vs 25 mg in non-alcoholic fatty liver disease
IRCT20250314065071N1Phase 2Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of empagliflozin in metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Zanjan University of Medical Sciences. Primary endpoints: Change in anthropometric indices and Change in liver enzymes. Started Apr 2025; status: completed.
02
Drugs
empagliflozin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20250314065071N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250314065071N1.